Polivy Trial Overview
Polivy (polatuzumab vedotin), approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), was studied in the Phase III POLARIX trial (NCT03274492). This trial compared Polivy plus BR (bendamustine-rituximab) against BR alone in 443 patients, with progression-free survival (PFS) as the primary endpoint. Median age was 69 years (range 18-89), and about 44% of patients were 70 or older.[1][2]
Age Breakdown in Patient Demographics
Patients were stratified by age: 56% under 70 and 44% 70+. Baseline characteristics showed older patients (≥70) had slightly higher rates of high-risk features like elevated LDH (52% vs. 46%) and ECOG performance status ≥2 (11% vs. 7%), but similar International Prognostic Index (IPI) scores across groups.[2]
PFS Outcomes by Age Group
Polivy-BR improved PFS across ages:
- Patients <70 years: Hazard ratio (HR) 0.58 (95% CI 0.40-0.85), reducing risk by 42%.
- Patients ≥70 years: HR 0.70 (95% CI 0.47-1.03), reducing risk by 30%, though not statistically significant (p=0.07 for interaction).
Median PFS was 15.8 months (Polivy-BR) vs. 8.6 months (BR) in <70 group, and 12.0 vs. 8.7 months in ≥70 group. Benefit was consistent but attenuated in older patients.[2][3]
Overall Survival and Other Endpoints
No significant age interaction for overall survival (OS): HR 0.73 (95% CI 0.49-1.09) overall, with similar trends in subgroups. Complete response rates were higher with Polivy-BR (40% vs. 18% <70; 36% vs. 20% ≥70). Adverse events, including Grade 3-4 neutropenia (43% vs. 36% <70; 41% vs. 33% ≥70), showed no disproportionate age-related increase.[2]
Why Age May Influence Results
Older patients had more aggressive disease biology and comorbidities, potentially limiting benefit magnitude. Subgroup analyses confirmed no formal interaction (p=0.37 for PFS), indicating Polivy-BR efficacy holds regardless of age, though absolute gains are smaller in those ≥70.[3]
Sources
[1]: FDA Approval Summary for Polivy
[2]: POLARIX Trial Publication, NEJM 2022
[3]: Genentech POLARIX Subgroup Analysis